Siri Lagethon Heck

• Øvrebotten, Tarjei; Mecinaj, Albulena; Stavem, Knut; Ghanima, Waleed; Brønstad, Eivind & Durheim, Michael Thomas [Show all 14 contributors for this article] (2024). Trajectory of cardiac troponin T following moderate-to-severe COVID-19 and the association with cardiac abnormalities. BMC Cardiovascular Disorders. ISSN 1471-2261. 24(1). doi: 10.1186/s12872-024-03854-7.
• Mecinaj, Albulena; Gulati, Geeta; Ree, Anne Hansen; Gravdehaug, Berit; Røsjø, Helge Rørvik & Steine, Kjetil [Show all 10 contributors for this article] (2024). Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction. JACC: CardioOncology. ISSN 2666-0873. 6(1), p. 83–95. doi: 10.1016/j.jaccao.2023.10.008.
• Øvrebotten, Tarjei; Heck, Siri Lagethon; Skjørten, Ingunn; Einvik, Gunnar; Stavem, Knut & Ingul, Charlotte Ingeborg Björk [Show all 8 contributors for this article] (2023). Minor Myocardial Scars in Association with Cardiopulmonary Function after COVID-19. Cardiology. ISSN 0008-6312. 148(4), p. 300–306. doi: 10.1159/000530942. Full text in Research Archive
• Omland, Torbjørn; Heck, Siri Lagethon & Gulati, Geeta (2022). The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. ISSN 2666-0873. 4(1), p. 19–37. doi: 10.1016/j.jaccao.2022.01.101. Full text in Research Archive Show summary

  Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and targeted cancer therapies. Both general measures and specific pharmacologic cardioprotective interventions as well as imaging- and biomarker-based surveillance strategies to identify patients at high risk have been tested in randomized controlled trials to prevent or attenuate cancer therapy–related cardiotoxic effects. Although meta-analyses including early trials suggest an overall beneficial effect, there is substantial heterogeneity in results. Recent randomized controlled trials of neurohormonal inhibitors in patients receiving anthracyclines and/or human epidermal growth factor receptor 2–targeted therapies have shown a lower rate of cancer therapy–related cardiac dysfunction than previously reported and a modest or no sustained effect of the interventions. Data on preventive cardioprotective strategies for novel cancer drugs are lacking. Larger, prospective multicenter randomized clinical trials testing traditional and novel interventions are required to more accurately define the benefit of different cardioprotective strategies and to refine risk prediction and identify patients who are likely to benefit.

• Mecinaj, Albulena; Gulati, Geeta; Heck, Siri Lagethon; Holte, Espen; Fagerland, Morten Wang & Larsen, Alf Inge [Show all 10 contributors for this article] (2021). Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardio-Oncology. ISSN 2057-3804. 7. doi: 10.1186/s40959-021-00115-w. Full text in Research Archive Show summary

  Objective To assess if sacubitril/valsartan given concomitantly with early breast cancer treatment regimens including anthracyclines, with or without trastuzumab, may prevent cardiac dysfunction. Methods PRADA II is a randomized, placebo-controlled, double blind, multi-center, investigator-initiated clinical trial. Breast cancer patients from four university hospitals in Norway, scheduled to receive (neo-)adjuvant chemotherapy with epirubicin independently of additional trastuzumab/pertuzumab treatment, will be randomized 1:1 to sacubitril/valsartan or placebo. The target dose is 97/103 mg b.i.d. The patients will be examined with cardiovascular magnetic resonance (CMR), echocardiography, circulating cardiovascular biomarkers and functional testing at baseline, at end of anthracycline treatment and following 18 months after enrolment. The primary outcome measure of the PRADA II trial is the change in left ventricular ejection fraction (LVEF) by CMR from baseline to 18 months. Secondary outcomes include change in LV function by global longitudinal strain by CMR and echocardiography and change in circulating cardiac troponin concentrations. Results The study is ongoing. Results will be published when the study is completed. Conclusion PRADA II is the first randomized, placebo-controlled study of sacubitril/valsartan in a cardioprotective setting during (neo-)adjuvant breast cancer therapy. It may provide new insight in prevention of cardiotoxicity in patients receiving adjuvant or neo-adjuvant therapy containing anthracyclines. Furthermore, it may enable identification of patients at higher risk of developing cardiotoxicity and identification of those most likely to respond to cardioprotective therapy. Trial registration The trial is registered in the ClinicalTrials.gov registry (identifier NCT03760588). Registered 30 November 2018.

• Myhre, Peder Langeland; Heck, Siri Lagethon; Skranes, Julia Brox; Prebensen, Christian Haugland; Jonassen, Christine M & Berge, Trygve [Show all 15 contributors for this article] (2021). Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity. American Heart Journal. ISSN 0002-8703. 242, p. 61–70. doi: 10.1016/j.ahj.2021.08.001. Full text in Research Archive
• Heck, Siri Lagethon; Mecinaj, Albulena; Ree, Anne Hansen; Hoffmann, Pavel; Schulz-Menger, Jeanette & Fagerland, Morten [Show all 12 contributors for this article] (2021). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): Extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. ISSN 0009-7322. 143(25), p. 2431–2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Full text in Research Archive
• Heck, Siri Lagethon; Gulati, Geeta; HOFFMANN, PAVEL; von Knobelsdorff-Brenkenhoff, Florian; Storås, Tryggve & Ree, Anne Hansen [Show all 12 contributors for this article] (2018). Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: The PRADA trial. European Heart Journal-Cardiovascular Imaging. ISSN 2047-2404. 19(5), p. 544–552. doi: 10.1093/ehjci/jex159. Full text in Research Archive Show summary

  Aims: Anthracycline treatment may cause myocyte loss and expansion of the myocardial extracellular volume (ECV) fraction by oedema and fibrosis. We tested the hypotheses that adjuvant treatment for early breast cancer with the anthracycline epirubicin is dose dependently associated with increased ECV fraction and total ECV, as well as reduced total myocardial cellular volume, and that these changes could be prevented by concomitant angiotensin or beta-adrenergic blockade. Methods and results: PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA) was a 2 × 2 factorial, placebo-controlled, double-blinded trial of candesartan and metoprolol. Sixty-nine women had valid ECV measurements. ECV fraction, total ECV, and total cellular volume were measured by cardiovascular magnetic resonance before and at the completion of anthracycline therapy. ECV fraction increased from 27.5 ± 2.7% to 28.6 ± 2.9% (P = 0.002). A cumulative doxorubicin equivalent dose of 268 mg/m2 was associated with greater increase in ECV fraction than doses <268 mg/m2 (mean change 3.4% [95% confidence interval (CI) 1.2, 5.5] vs. 0.7% [95% CI 0.0, 1.5], P = 0.006), as well as greater increase in total ECV (1.9 mL [95% CI 0.4, 3.5] vs. 0.1 mL [95% CI -0.6, 0.8], P = 0.04). In patients receiving candesartan, total cellular volume decreased (-3.5 mL [95% CI - 4.7, -2.2], P < 0.001) while in patients not receiving candesartan, it remained unchanged (P = 0.45; between group difference P = 0.003). Conclusions: Anthracycline therapy is associated with dose-dependent increase in ECV fraction and total ECV. Concomitant treatment with candesartan reduces left ventricular total cellular volume.

• Gulati, Geeta; Heck, Siri Lagethon; Røsjø, Helge; Ree, Anne Hansen; HOFFMANN, PAVEL & Hagve, Tor-Arne [Show all 11 contributors for this article] (2017). Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: Results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 6(11). doi: 10.1161/JAHA.117.006513. Full text in Research Archive
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; HOFFMANN, PAVEL; Schulz-Menger, Jeanette & Fagerland, Morten [Show all 15 contributors for this article] (2016). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal. ISSN 0195-668X. 37(21), p. 1671–1680. doi: 10.1093/eurheartj/ehw022.
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; Gravdehaug, Berit; Røsjø, Helge & Steine, Kjetil [Show all 10 contributors for this article] (2013). Cardioprotective treatment during adjuvant cancer therapy. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(17), p. 1832–1836. doi: 10.4045/tidsskr.12.1514.
• Heck, Siri Lagethon; Gulati, Geeta; Ree, Anne Hansen; Schulz-Menger, Jeanette; Gravdehaug, Berit & Røsjø, Helge [Show all 11 contributors for this article] (2012). Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology. ISSN 0008-6312. 123(4), p. 240–247. doi: 10.1159/000343622.
• Heck, Siri Lagethon; Blom, Peter & Berstad, Audun Elnæs (2006). Accuracy and complications in computed tomography fluoroscopy-guided needle biopsies of lung masses. European Radiology. ISSN 0938-7994. 16(6). doi: 10.1007/s00330-006-0152-2.

View all works in Cristin

• Heck, Siri Lagethon; Gulati, Geeta; HOFFMANN, PAVEL; von Knobelsdorff-Brenkenhoff, Florian; Storås, Tryggve & Ree, Anne Hansen [Show all 11 contributors for this article] (2016). Effects of Candesartan and Metoprolol on Myocardial Mass, Edema, and Fibrosis During Anthracycline Treatment in Early Breast Cancer: APRADA-CMR substudy.
• Heck, Siri Lagethon; Gulati, Geeta; von Knobelsdorff-Brenkenhoff, Florian; Storås, Trygve H; Schulz-Menger, Jeanette & HOFFMANN, PAVEL [Show all 7 contributors for this article] (2016). Validation of myocardial extracellular volume equation by serial cardiac magnetic resonance imaging measurements in patients with varying hematocrit.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Gravdehaug, Berit; Ree, Anne Hansen & HOFFMANN, PAVEL [Show all 9 contributors for this article] (2016). Atrio-ventricular plane excursion is impaired after ten weeks of anthracycline treatment in breast cancer patients; Data from the PRADA-study.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Gravdehaug, Berit; HOFFMANN, PAVEL & Steine, Kjetil [Show all 9 contributors for this article] (2016). Troponin I and Cardiac Function During Breast Cancer Therapy in Human Epidermal Growth Factor Receptor 2 Positive and Negative Patients: Results from the PRADA Study.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Fagerland, Morten; HOFFMANN, PAVEL & Gravdehaug, Berit [Show all 10 contributors for this article] (2016). Effect of candesartan and metoprolol on subclinical myocardial injury during anthracycline therapy: data from the prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) study.
• Gulati, Geeta; Heck, Siri Lagethon; HOFFMANN, PAVEL; Ree, Anne Hansen; Schulz-Menger, Jeanette & von Knobelsdorff-Brenkenhoff, Florian [Show all 12 contributors for this article] (2016). Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial. Circulation. ISSN 0009-7322.
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; Bratland, Åse; Steine, Kjetil & Schulz-Menger, Jeanette [Show all 11 contributors for this article] (2015). Abstract CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study. Cancer Research. ISSN 0008-5472.

View all works in Cristin